Home/Pipeline/BRIMOCHOL™ PF

BRIMOCHOL™ PF

Presbyopia

NDA SubmittedActive

Key Facts

Indication

Presbyopia

Phase

NDA Submitted

Status

Active

Company

Tenpoint Therapeutics

About Tenpoint Therapeutics

Tenpoint Therapeutics is a private, clinical-stage biotech developing novel treatments for age-related vision decline, with a lead program in presbyopia. The company's strategy centers on addressing key unmet needs in functional near vision, duration of effect, and tolerability for daily use. With its lead asset, BRIMOCHOL™ PF, having achieved an FDA New Drug Application (NDA) acceptance, Tenpoint is positioned for a potential near-term commercial launch in a large, underserved market. The company represents a specialized player in the ophthalmology space, aiming to set a new standard in presbyopia care.

View full company profile

Therapeutic Areas

Ophthalmology Age-Related Vision Decline

Other Presbyopia Drugs

Drug	Company	Phase	Status
Presbyopia Treatment	Viatris (2)	Filed/Under Review	Active
Flexivue Microlens	Presbia	Approved	Active
LB-01	Lento Bio	Discovery/IND-Enabling	Active
LB-02	Lento Bio	Discovery	Active
Presbyopia-Correcting Contact Lenses	Clerio Vision	Development	Active
Intra-corneal Implant	MAG Optics	Pre-clinical	Active
Novel Presbyopia & Refractive Therapies	Bausch + Lomb	Clinical Development	Active
NVK029	Vyluma	Phase 2	Active
ArtiPlus	Ophtec	Clinical Trials	Active
DE-128A	Santen Pharmaceutical	Phase 2	Active
YP-10	Viatris	NDA Filed	Under FDA Review (PDUFA date set)
VIZZ™ (aceclidine ophthalmic solution) 1.44%	LENZ Therapeutics	Approved	Commercial Launch